affno abstract
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial2016· article· en· The Lancet Oncology· Medicine
939
citations
Every work in the frame. Each row carries the routes that admitted it, because a frame that forgets how it found something cannot be audited.